Helen McIlleron1, Paolo Denti1, Silvia Cohn2, Fildah Mashabela3, Jennifer D Hoffmann2, Saba Shembe3, Regina Msandiwa3, Lubbe Wiesner1, Sithembiso Velaphi3,4, Sanjay G Lala3,4, Richard E Chaisson2, Neil Martinson3, Kelly E Dooley2. 1. Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa. 2. Johns Hopkins University Center for Tuberculosis Research, School of Medicine, Baltimore, MD, USA. 3. Perinatal HIV Research Unit (PHRU), MRC Soweto Matlosana Collaborating Center for HIV/AIDS and TB, University of the Witwatersrand, South Africa. 4. Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Abstract
Background: Newborns of HIV-infected mothers are given daily doses of nevirapine to prevent HIV-1 acquisition. Infants born to mothers with TB should also receive TB preventive therapy. TB preventive regimens include isoniazid for 6 months or rifampicin plus isoniazid for 3 months (RH preventive therapy). The effect of concomitant RH preventive therapy on nevirapine concentrations in infants is unknown. Patients and methods: Tshepiso was a prospective case-control cohort study of pregnant HIV-infected women with and without TB whose newborn infants received standard doses of nevirapine for HIV prophylaxis. Infants born to mothers with TB also received RH preventive therapy. Infant plasma nevirapine concentrations were measured at 1 and 6 weeks. The effects of RH preventive therapy on nevirapine disposition were investigated in a population pharmacokinetic model. Results: Of 164 infants undergoing pharmacokinetic sampling, 46 received RH preventive therapy. After adjusting for weight using allometric scaling, the model estimated a 33% reduction in nevirapine trough concentrations with RH preventive therapy compared with TB-unexposed infants not receiving concomitant rifampicin and a 30% decline in trough concentrations in a typical infant between day 7 and 35 post-partum. Conclusions: Rifampicin-based TB preventative treatment reduces nevirapine concentrations significantly in HIV-exposed infants. Although the nevirapine exposures required to prevent HIV acquisition in breastfeeding infants are undefined, given the potential risks associated with underdosing nevirapine in this setting, it is prudent to avoid rifampicin-based preventive therapy in HIV-exposed children receiving prophylactic nevirapine.
Background: Newborns of HIV-infected mothers are given daily doses of nevirapine to prevent HIV-1 acquisition. Infants born to mothers with TB should also receive TB preventive therapy. TB preventive regimens include isoniazid for 6 months or rifampicin plus isoniazid for 3 months (RH preventive therapy). The effect of concomitant RH preventive therapy on nevirapine concentrations in infants is unknown. Patients and methods: Tshepiso was a prospective case-control cohort study of pregnant HIV-infectedwomen with and without TB whose newborn infants received standard doses of nevirapine for HIV prophylaxis. Infants born to mothers with TB also received RH preventive therapy. Infant plasma nevirapine concentrations were measured at 1 and 6 weeks. The effects of RH preventive therapy on nevirapine disposition were investigated in a population pharmacokinetic model. Results: Of 164 infants undergoing pharmacokinetic sampling, 46 received RH preventive therapy. After adjusting for weight using allometric scaling, the model estimated a 33% reduction in nevirapine trough concentrations with RH preventive therapy compared with TB-unexposed infants not receiving concomitant rifampicin and a 30% decline in trough concentrations in a typical infant between day 7 and 35 post-partum. Conclusions: Rifampicin-based TB preventative treatment reduces nevirapine concentrations significantly in HIV-exposed infants. Although the nevirapine exposures required to prevent HIV acquisition in breastfeeding infants are undefined, given the potential risks associated with underdosing nevirapine in this setting, it is prudent to avoid rifampicin-based preventive therapy in HIV-exposed children receiving prophylactic nevirapine.
Authors: Neil A Martinson; Lynn Morris; Glenda Gray; Daya Moodley; Visva Pillay; Sarah Cohen; Puleng Dhlamini; Adrian Puren; Schene Bhayroo; Jan Steyn; James A McIntyre Journal: J Acquir Immune Defic Syndr Date: 2007-02-01 Impact factor: 3.731
Authors: Michael G Hudgens; Taha E Taha; Saad B Omer; Denise J Jamieson; Hana Lee; Lynne M Mofenson; Charles Chasela; Athena P Kourtis; Newton Kumwenda; Andrea Ruff; Abubaker Bedri; J Brooks Jackson; Philippa Musoke; Robert C Bollinger; Nikhil Gupte; Michael C Thigpen; Allan Taylor; Charles van der Horst Journal: Clin Infect Dis Date: 2012-09-20 Impact factor: 9.079
Authors: Julie A E Nelson; Ali Fokar; Michael G Hudgens; Kara J Compliment; Justin Tyler Hawkins; Gerald Tegha; Deborah D Kamwendo; Dumbani Kayira; Innocent A Mofolo; Athena P Kourtis; Denise J Jamieson; Charles M Van Der Horst; Susan A Fiscus Journal: AIDS Date: 2015-10-23 Impact factor: 4.177
Authors: P G Miotti; T E Taha; N I Kumwenda; R Broadhead; L A Mtimavalye; L Van der Hoeven; J D Chiphangwi; G Liomba; R J Biggar Journal: JAMA Date: 1999-08-25 Impact factor: 56.272
Authors: Paolo Denti; Neil Martinson; Silvia Cohn; Fildah Mashabela; Jennifer Hoffmann; Reginah Msandiwa; Sandra Castel; Lubbe Wiesner; Richard E Chaisson; Helen McIlleron; Kelly E Dooley Journal: Antimicrob Agents Chemother Date: 2015-12-07 Impact factor: 5.191
Authors: Haileyesus Getahun; Alberto Matteelli; Ibrahim Abubakar; Mohamed Abdel Aziz; Annabel Baddeley; Draurio Barreira; Saskia Den Boon; Susana Marta Borroto Gutierrez; Judith Bruchfeld; Erlina Burhan; Solange Cavalcante; Rolando Cedillos; Richard Chaisson; Cynthia Bin-Eng Chee; Lucy Chesire; Elizabeth Corbett; Masoud Dara; Justin Denholm; Gerard de Vries; Dennis Falzon; Nathan Ford; Margaret Gale-Rowe; Chris Gilpin; Enrico Girardi; Un-Yeong Go; Darshini Govindasamy; Alison D Grant; Malgorzata Grzemska; Ross Harris; C Robert Horsburgh; Asker Ismayilov; Ernesto Jaramillo; Sandra Kik; Katharina Kranzer; Christian Lienhardt; Philip LoBue; Knut Lönnroth; Guy Marks; Dick Menzies; Giovanni Battista Migliori; Davide Mosca; Ya Diul Mukadi; Alwyn Mwinga; Lisa Nelson; Nobuyuki Nishikiori; Anouk Oordt-Speets; Molebogeng Xheedha Rangaka; Andreas Reis; Lisa Rotz; Andreas Sandgren; Monica Sañé Schepisi; Holger J Schünemann; Surender Kumar Sharma; Giovanni Sotgiu; Helen R Stagg; Timothy R Sterling; Tamara Tayeb; Mukund Uplekar; Marieke J van der Werf; Wim Vandevelde; Femke van Kessel; Anna van't Hoog; Jay K Varma; Natalia Vezhnina; Constantia Voniatis; Marije Vonk Noordegraaf-Schouten; Diana Weil; Karin Weyer; Robert John Wilkinson; Takashi Yoshiyama; Jean Pierre Zellweger; Mario Raviglione Journal: Eur Respir J Date: 2015-09-24 Impact factor: 16.671
Authors: Sylvia M LaCourse; Barbra A Richardson; John Kinuthia; A J Warr; Elizabeth Maleche-Obimbo; Daniel Matemo; Lisa M Cranmer; Jerphason Mecha; Jaclyn N Escudero; Thomas R Hawn; Grace John-Stewart Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 9.079
Authors: H J Zar; D P Moore; S Andronikou; A C Argent; T Avenant; C Cohen; R J Green; G Itzikowitz; P Jeena; R Masekela; M P Nicol; A Pillay; G Reubenson; S A Madhi Journal: Afr J Thorac Crit Care Med Date: 2020-10-13
Authors: Nicole Salazar-Austin; Jennifer Hoffmann; Silvia Cohn; Fildah Mashabela; Ziyaad Waja; Sanjay Lala; Christopher Hoffmann; Kelly E Dooley; Richard E Chaisson; Neil Martinson Journal: Clin Infect Dis Date: 2018-03-05 Impact factor: 9.079
Authors: David W Haas; Anthony T Podany; Yajing Bao; Susan Swindells; Richard E Chaisson; Noluthando Mwelase; Khuanchai Supparatpinyo; Lerato Mohapi; Amita Gupta; Constance A Benson; Paxton Baker; Courtney V Fletcher Journal: Pharmacogenet Genomics Date: 2021-01 Impact factor: 2.000
Authors: Tom G Jacobs; Elin M Svensson; Victor Musiime; Pablo Rojo; Kelly E Dooley; Helen McIlleron; Rob E Aarnoutse; David M Burger; Anna Turkova; Angela Colbers Journal: J Antimicrob Chemother Date: 2020-12-01 Impact factor: 5.790